Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 17/20 | 0.49 |
| ▸ | CDK2 | P24941 | 17/20 | 0.49 |
| ▸ | CCND1 | P24385 | 16/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.49 |
| ▸ | CDK4 | P11802 | 6/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.49 |
| ▸ | CDK9 | P50750 | 6/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | RB1 | P06400 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156039 | 0.96 | CCNE1 (0.47) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3677106 | 0.96 | CCNE1 (0.47) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3682551 | 0.96 | CCNE1 (0.47) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3673162 | 0.93 | MAPK8 (0.53) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3669275 | 0.92 | MAPK14 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3673601 | 0.92 | CCNE1 (0.52) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3674916 | 0.92 | MAPK14 (0.52) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3678203 | 0.91 | CCNE1 (0.63) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3670491 | 0.91 | MAPK14 (0.52) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL3667827 | 0.90 | MAPK8 (0.55) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | CCNE1 863/4885CDK2 393/4885CCND1 539/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CCNE1 4327/4885CDK2 944/4885CCND1 4075/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CCNE1 4312/4885CDK2 936/4885CCND1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.